Primordial Genetics today announced the first closing of its Series A-2 financing round, including a group of 5 private investors.
The company will use the capital it has raised to support additional R&D activities to develop superior microbial strains for production of high-value proteins including human therapeutic proteins and industrial enzymes.


Leave a reply

Your email address will not be published. Required fields are marked *


Primordial World HQ

3550 General Atomics Court Building 2, Suite 400 San Diego, CA 92121

(858) 366-0770

Pushing the frontiers of Constructive Biology

©2021 Primordial Genetics, Inc.

Contact Us

You have questions and we have answers.


Log in with your credentials

Forgot your details?